Race/ethnic and sex differences in the initiation of non-statin lipid-lowering medication following myocardial infarction.
Sign Up to like & getrecommendations! Published in 2021 at "Journal of clinical lipidology"
DOI: 10.1016/j.jacl.2021.08.001
Abstract: BACKGROUND Adults with atherosclerotic cardiovascular disease (ASCVD) at very high-risk for recurrent events who have low-density lipoprotein cholesterol ≥ 70 mg/dL despite maximally-tolerated statin therapy are recommended to initiate ezetimibe or a proprotein convertase subtilisin/kexin type 9… read more here.
Keywords: pcsk9 inhibitor; inhibitor; initiation; ezetimibe pcsk9 ... See more keywords
FAMILIAL HYPERCHOLESTEREMIA: WHEN STATINS, EZETIMIBE & PCSK9 INHIBITORS ARE NOT ENOUGH
Sign Up to like & getrecommendations! Published in 2018 at "Journal of the American College of Cardiology"
DOI: 10.1016/s0735-1097(18)32980-2
Abstract: Patients with familial hypercholesteremia (FH) require lipoprotein aphaeresis (LA), mipomersen or lomitapide to control their LDL-C. Proprotein convertase subtisilin kexin type 9 (PCSK9) inhibitors have reduced the use of these treatment strategies but some FH… read more here.
Keywords: statins ezetimibe; pcsk9 inhibitors; hypercholesteremia statins; ezetimibe pcsk9 ... See more keywords
Recommendations for use of ezetimibe and/or PCSK9 inhibitors in patients with elevated LDL-C
Sign Up to like & getrecommendations! Published in 2022 at "Annals of Internal Medicine"
DOI: 10.7326/j22-0060
Abstract: SOURCE CITATION Hao Q, Aertgeerts B, Guyatt G, et al. PCSK9 inhibitors and ezetimibe for the reduction of cardiovascular events: a clinical practice guideline with risk-stratified recommendations. BMJ. 2022;377:e069066. 35508320. read more here.
Keywords: inhibitors patients; use ezetimibe; pcsk9 inhibitors; recommendations use ... See more keywords